Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis

[1]  Anders Axelsson,et al.  The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review. , 2011, International journal of pharmaceutics.

[2]  K. D. Atabay,et al.  High angiogenic potential in an in vivo rat corneal model is associated with shorter disease-free survival in low-grade oligodendrogliomas , 2011, Journal of Clinical Neuroscience.

[3]  T. KiliÇ,et al.  Relationship of Angiogenic Potential With Clinical Features in Cranial Meningiomas: A Corneal Angiogenesis Study , 2010, Neurosurgery.

[4]  Lin Zheng,et al.  The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. , 2010, Biomaterials.

[5]  Da-Ren Chen,et al.  Release profile characteristics of biodegradable-polymer-coated drug particles fabricated by dual-capillary electrospray. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[6]  K. Post,et al.  Expression of Angiogenic Factors in Craniopharyngiomas: Implications for Tumor Recurrence , 2010, Neurosurgery.

[7]  Lai Yeng Lee,et al.  Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. , 2009, Biomaterials.

[8]  P. Black,et al.  Local Delivery of Poly Lactic-co-glycolic Acid Microspheres Containing Imatinib Mesylate Inhibits Intracranial Xenograft Glioma Growth , 2009, Clinical Cancer Research.

[9]  Robert S Kerbel.  Tumor angiogenesis. , 2008, The New England journal of medicine.

[10]  A. Sav,et al.  Inhibition of angiogenesis induced by cerebral arteriovenous malformations using gamma knife irradiation. , 2007, Journal of neurosurgery.

[11]  F. Söylemezoğlu,et al.  TREATMENT OF MALIGNANT GLIOMAS WITH MITOXANTRONE‐LOADED POLY (LACTIDE‐CO‐GLYCOLIDE) MICROSPHERES , 2006, Neurosurgery.

[12]  G. Camenisch,et al.  Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier , 2006, Drug Metabolism and Disposition.

[13]  C. You,et al.  Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice. , 2006, Journal of neurosurgery.

[14]  C. You,et al.  Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. , 2006, Surgical neurology.

[15]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[16]  J. Benoit,et al.  Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  P. Black,et al.  Testing the Angiogenic Potential of Cerebrovascular Malformations by Use of a Rat Cornea Model: Usefulness and Novel Assessment of Changes over Time , 2005, Neurosurgery.

[18]  J. Warner,et al.  Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long‐term follow‐up , 2005, Clinical endocrinology.

[19]  R. Carroll,et al.  Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  B. Scheithauer,et al.  Angiogenesis and the growth potential of craniopharyngiomas , 2005, Endocrine pathology.

[21]  L. Shea,et al.  Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface , 2004, Experimental Neurology.

[22]  C. Marosi,et al.  Recurrent spinal ependymoma showing partial remission under Imatimib , 2004, Acta Neurochirurgica.

[23]  C. Berkland,et al.  PLG Microsphere Size Controls Drug Release Rate Through Several Competing Factors , 2003, Pharmaceutical Research.

[24]  Robert Langer,et al.  Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres , 1991, Pharmaceutical Research.

[25]  Nasim Akhtar,et al.  Angiogenesis Assays: Problems and Pitfalls , 2004, Cancer and Metastasis Reviews.

[26]  S. Feng,et al.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Nasim Akhtar,et al.  Angiogenesis assays: a critical overview. , 2003, Clinical chemistry.

[28]  B. Scheithauer,et al.  Angiogenesis in patients with craniopharyngiomas , 2002, Cancer.

[29]  P. Black,et al.  Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.

[30]  J L Cleland,et al.  Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[31]  J. Habrand,et al.  The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. , 1999, International journal of radiation oncology, biology, physics.

[32]  J. Honegger,et al.  Surgical treatment of craniopharyngiomas: experience with 168 patients. , 1999, Journal of neurosurgery.

[33]  Rakesh K. Jain,et al.  Quantitative angiogenesis assays: Progress and problems , 1997, Nature Medicine.

[34]  M. Shive,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .

[35]  O'donnell,et al.  Preparation of microspheres by the solvent evaporation technique. , 1997, Advanced drug delivery reviews.

[36]  Anderson,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres. , 1997, Advanced drug delivery reviews.

[37]  H. Okada,et al.  Biodegradable microspheres in drug delivery. , 1995, Critical reviews in therapeutic drug carrier systems.

[38]  L. Symon,et al.  Radical excision of craniopharyngioma by the temporal route: a review of 50 patients. , 1991, British journal of neurosurgery.

[39]  M. Yașargil,et al.  Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. , 1990, Journal of neurosurgery.